DMII Drugs Made In America Acquisition II Corp.

10.25USD+0.20%Mkt Cap: 652.92M USDP/E: 34.17

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other si…

Institutional holders20 on file

Key Statistics

Company
Market Cap652.92M USD
Enterprise Value651.98M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)4.19M USD
Revenue/Share—
Last Price10.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorFinancial Services
IndustryShell Companies
ISIN—
Valuation
P/E (Trailing)34.17
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-36.74
EPS (TTM)0.30 USD
EPS (Forward)—
52W Range
0.000099% of range10.33
52W High10.33 USD
52W Low0.0000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE0.86%
ROA0.83%
ROIC—
ROCE-0.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.02M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt275.03K USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio0.34
Quick Ratio0.27
Book Value/Sh-0.28 USD
Cash/Share0.0030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.63.70M
Float54.01M
Insiders15.27%
Institutions76.17%
Short Interest
Short Ratio0.4d
Short % Float0.16%
Short % Out.0.15%
Shares Short96.99K
Short (prev mo.)121.55K
Technical
SMA 5010.19 (+0.6%)
SMA 20010.08 (+1.7%)
Beta—
S&P 52W Chg12.08%
Avg Vol (30d)192.53K
Avg Vol (10d)78.71K
Technical Indicators
RSI (14)68.4
MACD0.0154
MACD Signal0.0143
MACD Hist.+0.0011
BB Upper10.26 USD
BB Middle10.22 USD
BB Lower10.18 USD
BB Width0.78%
ATR (14)0.2346 USD
Vol Ratio (20d)0.28x

About Drugs Made In America Acquisition II (NASDAQ: DMII)

›

Drugs Made In America Acquisition II (NASDAQ: DMII) is listed on Nasdaq, where its shares trade in USD. It belongs to the Shell Companies industry, part of the Financial Services sector.

The shares were at 10.25 USD on 19 November 2026.

At a market capitalisation of 652.92M USD, it trades at 34.2 times trailing earnings. The median trailing P/E of its 4 largest Shell Companies peers is 33.5, so DMII is valued in line with them.

Drugs Made In America Acquisition II reports return on equity of 0.9% and an operating margin of 0.0%.

Its debt exceeds its cash by 275.03K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.